OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)

  • A. Maraveyas, J. Waters, R. Roy, D. Propper, D. Fyfe, F. Lofts, G. Bozas, E. Gardiner, J. Sgouros, K.R. Wedgewood
  • Thrombosis Research, April 2010, Elsevier
  • DOI: 10.1016/s0049-3848(10)70037-2

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1016/s0049-3848(10)70037-2